Acquisition - August 15, 2019
AddLife acquires Danish companies
The company has signed an agreement for the acquisition of all shares in the Danish companies Lab-Vent Controls A/S and Koldt & Ryø El A/S. The companies are leaders on the Danish market in ventilation solutions for laboratories and cleanrooms. They will be a complement to AddLife´s operations in the company Holm & Halby, a […]
Acquisition - August 2, 2019
Norwegian bioinformatics company OncoImmunity acquired by NEC
OncoImmunity will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies in […]
Acquisition - July 5, 2019
Altimmune acquires Spitfire Pharma
The company announced earlier this summer that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). Spitfire, a portfolio company of Presidio Partners, was founded by John J. Nestor, Jr., Ph.D. and Velocity Pharmaceutical […]
Acquisition - July 1, 2019
UmanDiagnostics has been acquired by Quanterix Corp
Quanterix Corporation has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. The merger between the companies hold great promise to truly unlocking the value of NF-L, states UmanDiagnostics in their press release.”We are compelled by Quanterix’ […]
Acquisition - June 25, 2019
Karo Pharma acquires Trimb
The company has acquired all the shares of Trimb Holding AB from Avista Capital Partners and other shareholders for MSEK 3,400. The transaction is expected to contribute positively to Karo Pharma’s market position and create a strong platform for Karo Pharma’s continued growth. The combined company had annual sales of approximately MSEK 2,640 for 2018. […]
Acquisition - June 12, 2019
Sobi acquires emapalumab and related assets from Novimmune
Swedish Orphan Biovitrum (Sobi) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets. It has also announced a reorganization to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology. The acquisition gives Sobi access to world-class R&D capabilities […]
